A study from Utrecht University in the Netherlands found that many cancer drugs approved by the European Medicines Agency between 1995 and 2020 lack proof of added benefit. The researchers reported that a large proportion of these drugs offered minimal or no added benefit, especially those approved through fast-track pathways. The costs of these drugs may burden healthcare systems and give patients false hope. The study also highlighted the need for better alignment between regulatory and reimbursement processes to ensure the most effective drugs are developed for patients with the greatest needs. Global spending on oncology drugs is projected to rise, highlighting the importance of rational use and patient involvement in drug development processes.
Source link
Many European Cancer Drugs Offer No Added Benefit
